Activation of PPARγ by pioglitazone not only decreases the phosphorylation of STAT5 in CML cells but also reduces expression of STAT5 genes in quiescent and resistant CML stem cells [10]. The gene discussed is STAT5A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.